180 related articles for article (PubMed ID: 27163538)
41. Acute rejection features in dual kidney transplant recipients from elderly donors: comparison of calcineurin inhibitor-based and calcineurin inhibitor-free immunosuppressive protocols.
Aiello FB; Furian L; Marino S; Marchini F; Cardillo M; De Fazio N; Rigotti P; Valente M
Int J Immunopathol Pharmacol; 2009; 22(4):1001-7. PubMed ID: 20074463
[TBL] [Abstract][Full Text] [Related]
42. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
Borie DC; Changelian PS; Larson MJ; Si MS; Paniagua R; Higgins JP; Holm B; Campbell A; Lau M; Zhang S; Flores MG; Rousvoal G; Hawkins J; Ball DA; Kudlacz EM; Brissette WH; Elliott EA; Reitz BA; Morris RE
Transplantation; 2005 Apr; 79(7):791-801. PubMed ID: 15818321
[TBL] [Abstract][Full Text] [Related]
43. The kidney transplant program at the Bergamo Center.
Remuzzi G; Perico N; Gotti E; Ruggenenti P; Rota G; Locatelli G
Clin Transpl; 2000; ():179-91. PubMed ID: 11512311
[TBL] [Abstract][Full Text] [Related]
44. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
45. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
Gehringer M; Pfaffenrot E; Bauer S; Laufer SA
ChemMedChem; 2014 Feb; 9(2):277-81. PubMed ID: 24403205
[TBL] [Abstract][Full Text] [Related]
46. Mycophenolate mofetil-based immunosuppressive minimization and withdrawal strategies in renal transplantation: possible risks and benefits.
Meier-Kriesche HU
Curr Opin Nephrol Hypertens; 2006 Jun; 15 Suppl 1():S1-5. PubMed ID: 16829733
[TBL] [Abstract][Full Text] [Related]
47. Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile.
Djamali A; Pietrangeli CE; Gordon RD; Legendre C
Kidney Int Suppl; 2010 Sep; (118):S15-21. PubMed ID: 20706224
[TBL] [Abstract][Full Text] [Related]
48. Spleen tyrosine kinase contributes to acute renal allograft rejection in the rat.
Ramessur Chandran S; Tesch GH; Han Y; Woodman N; Mulley WR; Kanellis J; Blease K; Ma FY; Nikolic-Paterson DJ
Int J Exp Pathol; 2015 Feb; 96(1):54-62. PubMed ID: 25529862
[TBL] [Abstract][Full Text] [Related]
49. Calcineurin inhibitor-free protocols: risks and benefits.
Barbari AG; Stephan AG; Masri MA
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
[TBL] [Abstract][Full Text] [Related]
50. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.
Vincenti F; Tedesco Silva H; Busque S; O'Connell P; Friedewald J; Cibrik D; Budde K; Yoshida A; Cohney S; Weimar W; Kim YS; Lawendy N; Lan SP; Kudlacz E; Krishnaswami S; Chan G
Am J Transplant; 2012 Sep; 12(9):2446-56. PubMed ID: 22682022
[TBL] [Abstract][Full Text] [Related]
51. Long-term maintenance therapy with calcineurin inhibitors: an update.
Campistol JM
Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
[TBL] [Abstract][Full Text] [Related]
52. Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study.
Spagnoletti G; Favi E; Gargiulo A; Salerno MP; Citterio F
Transplant Proc; 2011 May; 43(4):1010-2. PubMed ID: 21620038
[TBL] [Abstract][Full Text] [Related]
53. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
54. Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy.
Alhamad T; Venkatachalam K; Daloul R; Brennan DC; Malone AF
Transplantation; 2017 Aug; 101(8):e287-e288. PubMed ID: 28422926
[No Abstract] [Full Text] [Related]
55. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation.
Roodnat JI; Hilbrands LB; Hené RJ; de Sévaux RG; Smak Gregoor PJ; Kal-van Gestel JA; Konijn C; van Zuilen A; van Gelder T; Hoitsma AJ; Weimar W
Transplantation; 2014 Jul; 98(1):47-53. PubMed ID: 24521775
[TBL] [Abstract][Full Text] [Related]
56. Cancer and mTOR Inhibitors in Transplant Recipients.
de Fijter JW
Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
[TBL] [Abstract][Full Text] [Related]
57. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
[TBL] [Abstract][Full Text] [Related]
58. Improved Long-Term Survival in Kidney Transplant Recipients with Donor-Specific HLA Antibodies After Mycophenolic Acid Escalation.
Rebellato LM; Parker K; Everly MJ; Briley KP; Kendrick W; Kendrick S; Haisch CE; Terasaki PI; Bolin P
Clin Transpl; 2014; ():137-42. PubMed ID: 26281138
[TBL] [Abstract][Full Text] [Related]
59. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
60. Can the early elimination of calcineurin inhibitors result in clinical benefits?
Weir MR
Transplant Proc; 2010 Nov; 42(9 Suppl):S16-20. PubMed ID: 21095444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
